Watch this on-demand Webcast on the evolving use of antibody–drug conjugates in the care of patients with advanced breast cancer from Clinical Care Options (CCO)
In this slideset from Clinical Care Options, a panel of international experts review the role of PARP inhibitors for patients with metastatic breast cancer.
Video from Clinical Care Options (CCO) with global perspectives on using PARP inhibitors in the care of patients with metastatic breast cancer
Commentary by Heather McArthur, MD: clinical implications of FDA approval for pembrolizumab plus chemotherapy in PD-L1–positive advanced TNBC from CCO
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.